1. Home
  2. BNR vs SGHT Comparison

BNR vs SGHT Comparison

Compare BNR & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

N/A

Current Price

$22.81

Market Cap

252.7M

Sector

Health Care

ML Signal

N/A

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

N/A

Current Price

$3.71

Market Cap

282.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BNR
SGHT
Founded
2014
2011
Country
China
United States
Employees
674
N/A
Industry
Medical Specialities
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
252.7M
282.9M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
BNR
SGHT
Price
$22.81
$3.71
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$9.08
AVG Volume (30 Days)
13.1K
351.0K
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.16
EPS
N/A
N/A
Revenue
N/A
$77,363,000.00
Revenue This Year
$136.32
$13.54
Revenue Next Year
N/A
$14.53
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$2.03
52 Week High
$41.72
$9.24

Technical Indicators

Market Signals
Indicator
BNR
SGHT
Relative Strength Index (RSI) 40.95 29.33
Support Level $7.99 $3.26
Resistance Level $24.23 $4.33
Average True Range (ATR) 2.07 0.35
MACD -0.41 -0.11
Stochastic Oscillator 29.88 5.80

Price Performance

Historical Comparison
BNR
SGHT

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Share on Social Networks: